NL-OMON53285尚未招募4 期
Multiple Sclerosis treatment with Autologous Hematopoietic Stem Cell Transplantation (MS-ACT): A long-term prospective observational study in the Netherlands - MS-ACT
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •All patients who undergo aHSCT for the treatment of RRMS in the Netherlands are
- •eligible to participate in this observational study.
排除标准
- •The only exclusion criteria for this observational study is unwillingness to
- •participate or to sign informed consent.
研究者
相似试验
招募中
不适用
Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the NetherlandsMultiple Sclerosis, Relapsing-RemittingNCT06567197Amsterdam UMC, location VUmc24
进行中（未招募）
1 期
Multiple sclerosis therapy with transdermal myelin peptide stimulation.relapsing-remitting multiple sclerosisEUCTR2016-002180-33-PLCentrum Neurologii Krzysztof Selmaj220
已完成
3 期
An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab10012303MSMultiple SclerosisNL-OMON41482Genzyme Corporation5
进行中（未招募）
1 期
An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabRelapsing Remitting Multiple SclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-010788-18-BEGenzyme Corporation1,500
进行中（未招募）
不适用
An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabEUCTR2009-010788-18-DKGenzyme Corporation1,500